Algert Global LLC Verve Therapeutics, Inc. Transaction History
Algert Global LLC
- $3.01 Billion
- Q2 2024
A detailed history of Algert Global LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 137,496 shares of VERV stock, worth $684,730. This represents 0.02% of its overall portfolio holdings.
Number of Shares
137,496Holding current value
$684,730% of portfolio
0.02%Shares
5 transactions
Others Institutions Holding VERV
# of Institutions
173Shares Held
74.7MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$61.5 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$26.2 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$22.6 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$19.3 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $299M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...